Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,419,026

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is Globus Medical (GMED) Down 28.9% Since Last Earnings Report?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

by Zacks Equity Research

Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

Zacks Equity Research

Globus Medical Gains From International Spine Arm, Innovation

by Zacks Equity Research

Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.

Zacks Equity Research

Globus Medical Stock Up on Solid '19 Preliminary Results

by Zacks Equity Research

Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.

Zacks Equity Research

Here's Why You Should Hold on to Globus Medical Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.

Zacks Equity Research

Globus Medical Rides on New Product Menu, U.S. Spine Business

by Zacks Equity Research

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

Zacks Equity Research

Globus Medical Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.

Zacks Equity Research

Why Is Globus Medical (GMED) Up 3.9% Since Last Earnings Report?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical's U.S. Spine Arm Grows, Product Launches Aid

by Zacks Equity Research

Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up

by Zacks Equity Research

Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Meet Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 0.00% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.

Zacks Equity Research

IART or GMED: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

IART vs. GMED: Which Stock Is the Better Value Option?

Zacks Equity Research

Globus Medical (GMED) Up 10.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

IART or GMED: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

IART vs. GMED: Which Stock Is the Better Value Option?

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up

by Zacks Equity Research

Globus Medical's (GMED) spine business gains traction from solid worldwide growth in the second quarter.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings Match Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 0.00% and 5.77%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Globus Medical (GMED) Q2 Earnings Expected to Decline

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Globus Medical (GMED) Down 13.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical Reveals Positive Study Results for ExcelsiusGPS

by Zacks Equity Research

Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)

by Zacks Equity Research

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak

by Zacks Equity Research

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of -12.20% and -1.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical (GMED) Reports Next Week: What Awaits?

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.